Fuyuan Pharmaceutical (601089.SH): The company's main products in the field of diabetes drugs are reprignide tablets, etc.

Gelonghui, April 17丨Fuyuan Pharmaceutical (601089.SH) said on the investor interactive platform that the company's main products in the field of diabetes drugs are regaglinide tablets, gliclazide sustained-release tablets, acarbose tablets, etc.

Gelonghui FinanceApr 17 15:37

Beijing Foyou PharmaLTD's (SHSE:601089) Earnings Are Weaker Than They Seem

Beijing Foyou Pharma CO.,LTD (SHSE:601089) announced strong profits, but the stock was stagnant. Our analysis suggests that shareholders have noticed something concerning in the numbers. SHSE:6010

Simply Wall StApr 10 07:28

Pacific released a research report on April 9 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) the growth rate of Q4 revenue is slowing, and the impact of collection is expected to be cl

Pacific released a research report on April 9 stating that it gave Fuyuan Pharmaceutical (601089.SH) a purchase rating. The main reasons for the rating include: 1) the growth rate of Q4 revenue is slowing, and the impact of collection is expected to be cleared within 2024; 2) the growth rate of the main business is steady, and the net interest rate continues to improve; 3) the increase in R&D investment and abundant reserves of products under development; 4) the increase in the dividend ratio to continue to give back to investors. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 9 18:33

Fuyuan Pharmaceutical (601089.SH): Has not cooperated with the Pangu Grand Model

Gelonghui, April 2 | Fuyuan Pharmaceutical (601089.SH) said on an interactive platform that the company has not cooperated with the Pangu Big Model at present.

Gelonghui FinanceApr 2 17:15

Express News | The Social Security Fund appeared as the top ten tradable shareholders of 192 individual stocks in the fourth quarter

BreakingsApr 1 08:21

Fuyuan Pharmaceutical (601089): Q4 performance was slightly lower than expected, profitability continued to increase throughout the year

Incident: The company released its 2023 annual report. In 2023, the company achieved operating income of 3.340 billion yuan, an increase of 3.07% over the previous year, and net profit to mother was 489 million yuan, an increase of 11.36% over the previous year, after deducting non-return to mother

太平洋證券Apr 1 00:00